NCT02090127No Longer Available不适用
Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
详细描述
This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Per original P05538 protocol
排除标准
- •Per original P05538 protocol
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibRelapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's LymphomaNCT04757259Alexion Pharmaceuticals, Inc.
No Longer Available
不适用
Flotetuzumab Expanded Access ProgramAcute Myeloid LeukemiaAML, Adult RecurrentAMLNCT04678466MacroGenics
Available
不适用
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009Breast Neoplasm Malignant FemaleNCT05134922Celcuity Inc
Approved For Marketing
不适用
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCLDLBCLNCT04300803MorphoSys AG
No Longer Available
不适用
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic CancerCancerNCT04869501I-Mab Biopharma US Limited